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Abstract: Epidermal growth factor receptor (EGFR) is a transmembrane 
glycoprotein, with an intracellular domain and tyrosine kinase function (TK) 
involved in cell proliferation. Dysfunctions in EGFR signaling pathways have 
been associated with oral malignant tumors such as oral squamous cell carci-
noma (OSCC). Dysfunctions of EGFR may result from: increased EGF ligand; 
EGFR overexpression and copy number gain of the EGFR gene (EGFR CNG); 
EGFR mutations; failure in the downregulation of EGFR; and EGFR crosstalk. 
Of these alterations, overexpression of EGFR is by far the most studied dys-
function in OSCC. Clinicians should identify possible alterations of EGFR in 
the oral mucosa of patients, as EGFR can act as a biomarker for the diagnosis 
and prognosis of OSCC. Currently, there are several methods and techniques for 
detecting EGFR. Immunohistochemistry (IHC), fluorescence in situ hybridiza-
tion (FISH) and polymerase chain reaction (PCR), are used to identify overex-
pression of EGFR, EGFR CNG and EGFR mutations, respectively. Detection 
of EGFR as a biomarker is key to identify any oral malignant transformation. 
Consequently, it becomes imperative to implement a non-invasive and inexpen-
sive method of early diagnosis for OSCC in clinical practice.
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INTRODUCTION.
In 1962, Dr. Cohen studied a protein extracted from the 
submandibular glands responsible for the early growth of 
the incisors and the eyelid in mice. In 1979, Cohen and Car-
penter named this protein epidermal growth factor (EGF).1,2 
EGF binds to its EGFR receptor by means of a covalent 
bond type.1 EGFR is a protein encoded by a gene located on 
the short arm of chromosome 7 (182-184), region p14-p12.2 
Its protein is a transmembrane glycoprotein receptor with 
1186 amino acids and 170 kDa. Through the TK cytoplas-
mic domain, they transduce signals from the cell membra-
ne to the nucleus, controlling cell proliferation, differentia-
tion, survival and motility.1,3,4
EGFR has been associated with tumorigenic, proli-
ferative, apoptotic, invasive and metastatic processes of 
epithelial origin.5 EGFR is involved in the pathogenesis of 
non-small-cell lung carcinoma (NSCLC), colorectal car-
cinomas, and oral squamous cell carcinoma (OSCC).6-11 
The use of EGFR as a molecular biomarker in conjunction 
with molecules involved in signal transduction are ideal 
targets for OSCC therapies and useful for early diagnosis, 
prognosis and treatment of cancer.12,13
In the last decade, the association of EGFR with carcino-
mas has increased the interest in its genomic evaluation. Mo-
lecular detection is performed through epithelial cell mem-
branes using diverse techniques depending on the objectives 
of each study.
The aim of this review is to describe the alterations in 
EGFR and identify the methods most commonly used to 
detect it in oral cancer.
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DYSREGULATION OF EGFR IN ORAL 
CANCER.
Dysregulation of EGFR in cancer has been extensively 
studied.6,9,14 Mechanisms involved in the dysregulation of 
EGFR are many, including: 
1) Increased EGF ligand;15 
2) Overexpression of EGFR and EGFR CNG;9,16 
3) EGFR mutations;17 
4) Failure in the downregulation of EGFR;18
5) EGFR crosstalk.7,19
Increased EGF ligand
Activation or inhibition of EGFR is determined by the 
binding of its ligands. Molecules that bind to EGFR inclu-
de EGF, amphiregulin, epigen, transforming growth factor 
alpha (TGF-α), betacellulin, heparin-binding EGF, epire-
gulin, neuregulin or heregulin and insulin-type growth 
factor. However, the main ligand of EGFR is EGF.15,20 
EGF is a single polypeptide chain comprising 53 amino 
acids.1 Increased synthesis of EGF has been associated 
with a number of tumors, including head and neck cancer 
(HNC).21,22 EGF contributes to the growth of malignant 
tumors by stimulating cell proliferation and migration. It 
also participates in the dysregulation of autophagic acti-
vity and tumor metastasis through metalloproteinases.18
Some therapies with monoclonal antibodies have had 
an anti-proliferative effect on cancer cells expressing 
EGFR.23,24 Cetuximab (ErbituxTM), a chimeric monoclo-
nal antibody, recognizes an epitope in the extracellular 
domain III of EGFR. It has been widely used in clinical 
studies due to its ability to inhibit EGFR by occupying 
the ligand-binding site, reducing the proliferation of 
cancer cells. However, it has been shown to have better 
anti-tumor effects when combined with chemotherapy 
or radiotherapy.25
Overexpression and increase in copy number of the 
EGFR gene
Hyperactivation and dimerization of EGFR play an im-
portant role in the regulation of the PI3K/AKT/mTOR 
pathway. The activation of this pathway revert autopha-
gy through inhibition of Beclin-1 tyrosine phosphoryla-
tion, which in turn prevents the formation of class III 
PIK3 complex, promoting epithelial neoplasm progres-
sion. Hyperactivation of the PI3K/AKT/mTOR pathway 
is associated with the development, growth and prolife-
ration of up to 50% of cancers.25  EGFR overexpression 
has been observed in epithelial-origin tumors as well as 
in NSCLC, renal, ovarian, breast, prostate cancer and 
colorectal carcinomas. 
In HNC, 70-90% of neoplasms present overexpression 
of EGFR.9 In OSCC, there has been observed an increase 
in EFGR expression in the cell plasma membrane of oral 
keratinocytes,26 resulting in a poor prognosis, high recu-
rrence and lower survival rate.9,16,26
EGFR mutations
EGFR mutations can be classified according to the spe-
cific region of the receptor they affect: extracellular, intra-
cellular or TK domain. Deletion type mutations affecting 
the sequence encoding the N-terminal region, deletions 
of exons 2-7, 12-13, 14-15, 25-27, 25-28; duplications of 
exons 2-7, 18-21, and point mutations have been descri-
bed. As a result, small deletions and insertions alter co-
don sequence producing proteins with aberrant function. 
These aberrant proteins may have a decreased activity or 
maintain a constitutive activation.3,17,27-30
The mutated variant, known as EGFR variant III 
(EGFRvIII ), encoded by EGFRvIII, has a deletion of 
exons 2-7, which encode the extracellular domain of li-
gand binding. The altered protein is constitutively acti-
ve with slow degradation, allowing more time to interact 
with its ligand. It is the most common EGFR mutation 
and the best described in relation to various malignan-
cies. EGFRvIII has been associated with increased tumor 
cell proliferation in mouse model and it has been obser-
ved that its presence is associated with a lower response 
to treatment with radiation therapy.3,16,30,31 McItyre et al.3 
studied the expression of EGFRvIII in OSCC, noting that 
this is overexpressed in 2% of patients. Melchers et al.31 
analyzed 531 cases of HNC and found no difference in the 
prevalence of the mutation compared to healthy controls. 
Khattri et al.28 found that only 2 (0.31%) out of 638 cases 
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had the EGFRvIII mutation. Therefore, this type of muta-
tion is extremely rare in HNC and OSCC.3,28,31
Mutations in exons 18, 19, 20 and 21 correspond to 
rare amino acid variations of the TK intracellular do-
main. About 90% of EGFR mutations are deletions lo-
cated in exon 19 and the L858R point mutation of exon 
21.29 Mutations in exon 20 encode proteins that norma-
lly are located after the C-helix of TK domain. This oc-
curs in 4% of all EGFR mutations, with T790M substi-
tution being the most prevalent, representing 50% of all 
mutations in exon 20.32
Hsieh et al.33 studied EGFR in patients with OSCC who 
chewed betel nut, finding that 30.36% had silent mutation 
at nucleotide 2607 in exon 20. This mutation does not alter 
the amino acid sequence and results in a mutation at co-
don 787 (Q787Q). They also identified two types of silent 
mutations in exon 21 which corresponded to 1.79% of the 
cases; however, they found no mutations in exons 18 and 
19. Furthermore, Nagalakshmi et al.17 studied EGFR mu-
tations in OSCC, finding that the samples studied showed 
mutations in exons 18 (nucleotides G2155C, G2176A), 19 
(nucleotide C2188G) and 21 (nucleotide G2471A), with 
frequencies of 44.96%, 32.55% and 65.11%, respectively.
Defects in EGFR downregulation
In normal conditions, after ligand binding, cytoplas-
mic tyrosine residues from EGFR are autophosphoryla-
ted, producing binding zones for various proteins. The 
recruitment of these proteins occurs in catalytic domains 
and/or scaffolds actively involved in cell signaling. An im-
portant pathway for deactivating TK receptors is downre-
gulation. In this process, the activated receptor is interna-
lized by the plasma membrane by means of endocytosis. 
Then, it is ubiquitinated and transported to the lysosomes 
where it is degraded by acid hydrolases. 
When the TK domain is not deactivated appropria-
tely, a failure in normal activity and operation of the 
receptor can occur.34,35 Yang et al.36 suggested that the 
ability of mutated EGFR to escape downregulation may 
be due to lack of: ubiquitin binding, dysregulation of 
kinase associated with cyclin-G, and reduced levels of 
CD82 (metastasis suppressor).
Zhen et al.34 studied the effect of curcumin on cultiva-
te cells from patients diagnosed with OSCC. The study 
concluded that curcumin revert growth of tumor cells by 
inhibiting EGFR phosphorylation. Curcumin is known 
for inhibiting the growth, invasion and metastasis of ma-
lignant cells and for inducing apoptosis in breast cancer.
Another molecule that has been studied in conjunction 
with EGFR, is E-cadherin. This molecule is responsible 
for preserving integrity and cell morphology. Wang et al.37 
observed that in vitro reduction of E-cadherin increases 
the upregulation of EGFR transcription. This suggests 
that loss of E-cadherin can induce proliferation of HNC 
by activating EGFR and its signaling pathways to the nu-
cleus. It is essential to determine if the increase in E-cad-
herin plays a role in the downregulation of EGFR.
EGFR crosstalk
Cytoplasmic and nuclear signaling pathways can be ac-
tivated by proteins acting at similar levels and conditions. 
This feature is known as crosstalk and is a form of evolu-
tionary compensation to avoid a receptor being activated 
by a single ligand. Crosstalk between EGFR and other 
members of the ErbB family, cytokine receptors, ion chan-
nels, G protein-coupled receptors and various cell adhe-
sion molecules has been described in the literature.38,39 The 
integrin family phosphorylates the TK domain increasing 
the receptor activity.40 Zein et al.38 studied the relationship 
that existed between the EGF-EGFR complexes and nerve 
growth factor with its receptor, finding that there is a bi-
directional crosstalk between ligands and their receptors.
In HNC it has been observed that some of the ligands 
that bind to G protein-coupled receptors activate EGFR 
pathway, contributing to carcinogenesis.39 It is suggested 
that stimulation of gastrin-releasing peptide receptor ac-
tives EGFR and modulates the growth and invasion of 
HNC.41 Egloff et al.19 characterized the expression and 
signaling of estrogen receptors (Era and Erb) in HNC in 
relation to the EGF-EGFR complex. At the level of signal 
transduction and transcription, they found that Era and 
Erb receptors were expressed and stimulated in HNC.
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Type of Alteration Laboratory Technique Authors
Increased EGF ligand ELISA Zhang et al.41 2014
 IHC Naik et al.48 2011
Overexpression of EGFR IHC Aquino et al.44 2012
 WB Zhang et al.41 2014
Copy Number Gain of EGFR gene RT-PCR Wang et al.37 2011
  Huang et al.45 2012
 FISH Aquino et al.44 2012
  Szabó et al.9 2011
 CISH Bernardes et al.47 
 Real Time-PCR Bagan et al.26 2012
EGFR mutations  McIntyre et al.3 2012
 PCR Nagalakshmi et al.17 2014
  Szabó et al.9 2011
  Khattri et al.28 2014
  Szabó et al.9 2011
 HRM Do et al.27 2008
 Q-PCR Khattri et al.28 2014
  Khattri et al.28 2014
  Melchers et al.31 2014
Defects in EGFR downregulation MMF Capuani et al.35 2015
 WB Zhen et al.34 2014
EGFR crosstalk  Egloff et al.19 2009
  Thomas et al.39 2006
 ELISA Zein et al.38 2010
Table 1. Laboratory technique by author according to EGFR alteration.
ELISA: Enzyme-linked immunosorbent assay. IHC: Immunohistochemistry. WB: Western Blot. RT-PCR: Polymerase chain reaction 
with reverse transcriptase. FISH: fluorescent in situ hybridization. CISH: Chromogenic In Situ Hybridization. Real time-PCR: Real-time 
polymerase chain reaction. PCR: Polymerase chain reaction. HRM: High resolution melting. Q-PCR: Quantitative polymerase chain 
reaction. MPM: Multi-site Phosphorylation Model
DETECTION METHODS OF EGFR IN ORAL 
CANCER.
Clinical significance of EGFR detection in oral mucosa lies 
in its role as a biomarker or indicator of malignant transfor-
mation, diagnosis, progression and prognosis of OSCC. The 
National Cancer Institute defines a biomarker as any molecule 
found in fluids or tissues that is a sign of a physiological or 
pathological process.42
Identification of EGFR as an indicator of malignant transfor-
mation is based on its overexpression in potentially malignant 
samples as leukoplakia and oral epithelial dysplasia (OED).16 
The expression of EGFR varies according to the degree of OED; 
expression is greater with increasing malignancy. Consequently, 
EGFR can be considered as a marker of cell epithelial prolifera-
tion, of OED, and as the onset of progression from dysplasia to 
OSCC.43 Bagan et al.26 reported that EGFR CNG is a potential 
marker for predicting malignant transformation of OED. The 
authors noted that EGFR CNG was significantly higher in ma-
lignant lesions and in non-homogeneous leukoplakia compared 
to homogeneous leukoplakia. Regarding OSCC, Aquino et al.44 
evaluated overexpression of EGFR protein and EGFR CNG by 
immunohistochemistry (IHC) and fluorescence in situ hybri-
dization (FISH), respectively. They found high expression of 
EGFR and EGFR CNG (14%), confirming the important role 
IHC
RT-PCR
WB
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of EGFR as a biomarker in OSCC.
Huang et al.45 found that EGFR CNG in samples of OSCC 
were associated with characteristics of local invasion, including 
bone and perineural invasion. In oral cancer, overexpression of 
EGFR has been associated with chemoresistance and a poor 
prognosis.18 EGFR CNG is a late event in oral carcinogenesis. In 
OSCC it ranges from 9% to 56% of cases, being more frequent 
in T3 and T4 stages.46 
However, other authors have concluded that there is no 
association between EGFR expression and EGFR CNG in 
OSCC. Moreover, neither of these changes was associated 
with clinicopathological features of OSCC. EGFR may 
be useful as a predictive marker, but it seems crucial to 
determine the best method to assess its relationship with 
alterations and cancer.47  There are several molecular tech-
niques with variable specificities and sensitivities for detec-
ting EGFR in oral mucosa and its association with various 
events in OSCC, (Table I).3,9,17,19,20,27,28,31,34,35,38,39,41,45,47,48 
The most widely used method for EGFR detection is IHC. 
It is a simple and relatively quick technique. However, it is 
semi-quantitative in nature, and can be affected by operator 
bias. Polymerase chain reaction (PCR) has been used to detect 
EGFR mutations in normal and neoplastic tissues.3,17,31,35,49 In 
oral cancer specific tests to evaluate deletions, silent mutations 
or changes at amino acid level encoded in exons 18 to 21 have 
been used.33 Bagan et al.26 studied the genomic amplification 
of EGFR in frozen tissue samples. Using Real-Time-PCR, they 
found a high rate of EGFR CNG in oral cancer when compared 
with potentially malignant lesions. It is also possible to study 
EGFR CNG by FISH and analyze somatic mutations in exons 
18 to 21 by high resolution melting (HRM). The latter method 
is fast, easy to use and inexpensive, but it is rarely used.27 Even 
with these advantages, more research with larger samples and 
new types of analyses is needed due to the high rate of false 
negatives.50
A relatively new diagnosis method is the identification of 
EGFR biomarkers using bio-nano-chip (BNC). The BNC 
sensor integrates multiple laboratory processes in a three-step 
microfluidic platform. A simultaneous analysis of the surface 
expression of the biomarker and cell morphology is performed 
using intensity and multiple key parameters. First, oral cells ex-
tracted by cytology are placed in the sensor by pressure driven 
flow. Captured cells are stained with fluorescent and immuno-
reactive dyes. Finally, stained cells are subjected to fluorescence 
analysis by 3D microscopy of the membrane surface. Resear-
chers have shown that the BNC sensor correctly identifies 
premalignant and malignant lesions in less than 45 minutes. 
However, authors emphatically suggest  creating a wider range 
of biomarkers for early detection of cancer and dysplasia.51 The 
Western Blot technique (WB), immunoblot or immunoblot-
ting, was used to assess EGFR dysregulation.36 In the same 
way, Wang et al.37 and Egloff et al.19 besides studying EGFR, 
used WB to quantify overexpression of E-cadherin and of the 
estrogen receptor, respectively.
CONCLUSION.
The most studied EGFR dysregulations in OSCC are recep-
tor overexpression and mutations by means of IHC, FISH and 
PCR. These techniques are costly and complex, so it is crucial 
to develop a low-cost, non-invasive and easy to use method.
Desregulación y métodos de detección del 
EGFR en cáncer oral. Revisión narrativa.
Resumen: El receptor del factor de crecimiento epidér-
mico (EGFR) es una glicoproteína transmembrana, con 
un dominio intracelular y función tirosina quinasa (TK) 
que participa en la proliferación celular. Las fallas en las 
vías de señalización del EGFR se han asociado con la for-
mación de tumores malignos orales como el carcinoma 
oral de células escamosas (COCE). El incorrecto funcio-
namiento del EGFR puede producirse por: aumento del 
ligando EGF; sobreexpresion del EGFR y ganancia en el 
número de copias del gen EGFR (GNC EGFR); mutacio-
nes del EGFR; falla en la regulación negativa del EGFR; 
y diafonía del EGFR. De las alteraciones mencionadas, 
la sobreexpresion de EGFR es por lejos la disfunción más 
estudiada en COCE. Para el clínico es importante poder 
identificar las posibles alteraciones del EGFR en la mu-
cosa oral del paciente, esto debido a que el EGFR puede 
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